Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 2/2019

21.08.2018 | Original Paper

Virological Non-suppression and Its Correlates Among Adolescents and Young People Living with HIV in Southern Malawi

verfasst von: Eric Umar, Judith A. Levy, Robert C. Bailey, Geri Donenberg, Ronald C. Hershow, Mary Ellen Mackesy-Amiti

Erschienen in: AIDS and Behavior | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

We examined virological non-suppression (VLN) among youth ages 13–24 years receiving HIV treatment in public health facilities in six southern Malawi districts. We also tested three ART adherence measures to determine how well each identified VLN: pill counts, a Likert scale item, and a visual analogue scale. VLN was defined as HIV RNA > 1000 copies/ml. Of the 209 youth, 81 (39%) were virally non-suppressed. Male gender and stigma were independently associated with VLN; social support and self-efficacy were independently protective. Pill count had the highest positive predictive value (66.3%). Using a pill count cut-off of < 80% nonadherence, 36 (17%) of the youth were non-adherent. Of the adherent, 120 (69%) were viral suppressed. Results indicate the need to address HIV-related stigma and to bolster social support and selfefficacy in order to enhance viral suppression. In the absence of viral load testing, pill count appears the most accurate means to assess VLN.
Literatur
1.
Slogrove AL, Sohn AH. The global epidemiologyof adolescents living with HIV: time for more granular data to improve adolescent health outcomes. Curr Opin HIV AIDS. 2018;13(3):170–8.PubMedPubMedCentral
2.
Kim MH, Mazenga AC, Yu X, et al. High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: barriers and associated factors. J Int AIDS Soc. 2017;20(1):1–12.CrossRef
3.
Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda August 2014–July 2015. BMC Infect Dis. 2017;17(1):326.CrossRefPubMedPubMedCentral
4.
Dworkin MS, Douglas GW, Sabilha Rani GP, Chakraborty A. Adherence to highly active antiretroviral therapy in Hyderabad, India: barriers, facilitators and identification of target groups. Int J STD AIDS. 2016;27(3):186–95.CrossRefPubMed
5.
Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.CrossRefPubMedPubMedCentral
6.
Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review. AIDS Care. 2015;27(7):805–16.CrossRefPubMed
7.
Ramaiya MK, Sullivan KA, O’Donnell K, et al. A qualitative exploration of the mental health and psychosocial contexts of HIV-positive adolescents in Tanzania. PLoS ONE. 2016;11(11):e0165936.CrossRefPubMedPubMedCentral
8.
Folayan M, Odetoyinbo Morolake, Brown B, Harrison A, et al. Addressing the socio-development needs of adolescents living with HIV/AIDS in Nigeria: a call for action. Afr J Reprod Health. 2014;18(3):93–101.PubMedPubMedCentral
9.
Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S. Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study. AIDS. 2015;29(10):1227–37.CrossRefPubMed
10.
Denison JA, Banda H, Dennis AC, et al. “The sky is the limit”: adhering to antiretroviral therapy and HIV self-management from the perspectives of adolescents living with HIV and their adult caregivers. J Int AIDS Soc. 2015;13(18):19358.CrossRef
11.
Kang E, Delzel DA, Chhabra M, Oberdorfer P. Factors associated with high rates of antiretroviral medication adherence among youth living with perinatal HIV in Thailand. Int J STD AIDS. 2015;26(8):534–41.CrossRefPubMed
12.
Xu L, Munir K, Kanabkaew C, Le Coeur S. Factors influencing antiretroviral treatment suboptimal adherence among perinatally HIV-infected adolescents in Thailand. PLoS ONE. 2017;12(2):e0172392.CrossRefPubMedPubMedCentral
13.
MacDonell KK, Jacques-Tiura AJ, Naar S, Fernandez MI. Predictors of self-reported adherence to antiretroviral medication in a multisite study of ethnic and racial minority HIV-positive youth. J Pediatr Psychol. 2016;41(4):419–28.CrossRefPubMed
14.
Ewart CK. Social action theory for a public health psychology. Am Psychol. 1991;46(9):931–46.CrossRefPubMed
15.
Traube DE, Holloway IW, Schrager SM, Kipke MD. Utilizing Social Action Theory as a framework to determine correlates of illicit drug use among young men who have sex with men. Psychol Addict Behav. 2012;26(1):78–88.CrossRefPubMed
16.
17.
Stewart RC, Umar E, Tomenson B, Creed F. Validation of screening tools for antenatal depression in Malawi–a comparison of the Edinburgh postnatal depression scale and self reporting questionnaire. J Affect Disord. 2013;150(3):1041–7.CrossRefPubMed
18.
Holzemer WL, Uys LR, Chirwa ML, et al. Validation of the HIV/AIDS stigma instrument—PLWA (HASI-P). AIDS Care. 2007;19(8):1002–12.CrossRefPubMed
19.
Stewart RC, Umar E, Tomenson B, Creed F. Validation of the multi-dimensional scale of perceived social support (MSPSS) and the relationship between social support, intimate partner violence and antenatal depression in Malawi. BMC Psychiatry. 2014;14:180.CrossRefPubMedPubMedCentral
20.
Nakimuli-Mpungu E, Mojtabai R, Alexandre PK, et al. Lifetime depressive disorders and adherence to anti-retroviral therapy in HIV-infected Ugandan adults: a case-control study. J Affect Disord. 2013;145(2):221–6.CrossRefPubMed
21.
Johnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV treatment adherence self-efficacy scale (HIV-ASES). J Behav Med. 2007;30(5):359–70.CrossRefPubMedPubMedCentral
22.
Douglas GP, Gadabu OJ, Joukes S, et al. Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. PLoS Med. 2010;7(8):e1000319.CrossRefPubMedPubMedCentral
23.
Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.CrossRefPubMedPubMedCentral
24.
Bezabhe WM, Charmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore). 2016;95(15):e3361.CrossRefPubMedPubMedCentral
25.
Centers for Disease Control and Prevention (CDC), ICAP, Columbia University Mailman School of Public Health, Johns Hopkins University, Ministry of Health (Malawi), Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Malawi College of Medicine, Westat. Malawi Population-Based HIV Impact Assessment 2015–2016. 2016.
26.
Smith C, Gengiah TN, Yende-Zuma N, Upfold M, Naidoo K. Assessing adherence to antiretroviral therapy in a rural paediatric cohort in KwaZulu-Natal, South Africa. AIDS Behav. 2016;20(11):2729–38.CrossRefPubMedPubMedCentral
27.
Kerschberger B, Boulle AM, Kranzer K. Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy. J Int AIDS Soc. 2015;18:20092.CrossRefPubMedPubMedCentral
28.
Zanoni BC, Archary M, Buchan S, Katz IT, Haberer JE. Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the cresting wave. BMJ Global Health. 2016;1(3):e000004.CrossRefPubMedPubMedCentral
29.
Cruz ML, Cardoso CA, Darmont MQ, et al. Viral suppression and adherence among HIV-infected children and adolescents on antiretroviral therapy: results of a multicenter study. J Pediatr (Rio J). 2014;90(6):563–71.CrossRef
30.
Saberi P, Mayer K, Vittinghoff E, Naar-King S. Correlation between use of antiretroviral adherence devices by HIV-infected youth and plasma HIV RNA and self-reported adherence. AIDS Behav. 2015;19(1):93–103.CrossRefPubMedPubMedCentral
31.
Burch LS, Smith CJ, Anderson J, et al. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health. 2016;1(1):e26–36.CrossRefPubMedPubMedCentral
32.
Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.CrossRefPubMedPubMedCentral
33.
Sutton SS, Magagnoli J, Hardin JW. Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV/AIDS patients receiving antiretroviral therapy. Pharmacotherapy. 2017;37(2):204–13.CrossRefPubMed
34.
Boily MC, Masse B, Alsallag R, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med. 2012;9(7):e1001250.CrossRefPubMedPubMedCentral
35.
Mave V, Gahunia M, Frontini M, Clark R, Mushatt D. Gender differences in HIV drug resistance mutations and virological outcome. J Womens Health (Larchmt). 2011;20(1):117–22.CrossRef
36.
Sumari-de Boer IM, Sprangers MA, Prins JM, Nieuwkerk PT. HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients. AIDS Behav. 2012;16(6):1681–9.CrossRefPubMed
37.
Croome N, Ahluwalia M, Hughes LD, Abas M. Patient-reported barriers and facilitators to antiretroviral adherence in Sub-Saharan Africa: a systematic review. AIDS. 2017;31(7):995–1007.CrossRefPubMed
38.
Tran BX, Nguyen LT, Nguyen NH, Hoang QV, Hwang J. Determinants of antiretroviral treatment adherence among HIV/AIDS patients: a multisite study. Glob Health Action. 2013;6:19570.CrossRefPubMed
39.
Reif S, Proeschold-Bell RJ, Yao J, et al. Three types of self-efficacy associated with medication adherence in patients with co-occurring HIV and substance use disorders, but only when mood disorders are present. J Multidiscip Healthc. 2013;6:229–37.PubMedPubMedCentral
40.
Abrams EJ, Strasser S, Kranzer K. 90-90-90—Charting a steady course to end the paediatric HIV epidemic. J Int AIDS Soc. 2015;18:20096.CrossRef
Metadaten
Titel
Virological Non-suppression and Its Correlates Among Adolescents and Young People Living with HIV in Southern Malawi
verfasst von
Eric Umar
Judith A. Levy
Robert C. Bailey
Geri Donenberg
Ronald C. Hershow
Mary Ellen Mackesy-Amiti
Publikationsdatum
21.08.2018
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 2/2019
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2255-6

Weitere Artikel der Ausgabe 2/2019

AIDS and Behavior 2/2019 Zur Ausgabe

Original Paper

Who Will Show? Predicting Missed Visits Among Patients in Routine HIV Primary Care in the United States

Original Paper

Suboptimal Retention in Care Among Recently Released Prisoners: Implications for Social Workers in HIV Primary Care

Original Paper

Timing and Predictors of Initiation on Antiretroviral Therapy Among Newly-Diagnosed HIV-Infected Persons in South Africa

Original Paper

Low-Intensity Outreach to Increase Uptake of HIV Preexposure Prophylaxis Among Patients with Sexually Transmitted Infections

Original Paper

Paediatric ART Adherence in South Africa: A Comprehensive Analysis

Original Paper

Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise